Startups
We create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations
We have built an integrated & iterative platform based on knowledge, experimentation, and simulation that allows us to better interrogate and harness the power of regulated apoptosis
We are developing a suite of orally active therapeutics which can act as single agents or in combination with other oncology therapies to create better and lasting outcomes for cancer patients
We have built an integrated & iterative platform based on knowledge, experimentation, and simulation that allows us to better interrogate and harness the power of regulated apoptosis
We are developing a suite of orally active therapeutics which can act as single agents or in combination with other oncology therapies to create better and lasting outcomes for cancer patients
Overview
Location
United States, New York, Kingston
Employees
1-10
Total raised
$25M
Founded date
2020
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 27, 2021 | Ipsen : BAKX collaboration-27 July 2021 | Disclaimer: Intended for international media and investor audiences only Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway... |
Reviews 0
FAQ about BAKX THERAPEUTICS
When was BAKX THERAPEUTICS founded?
BAKX THERAPEUTICS was founded in 2020.
How much funding has BAKX THERAPEUTICS raised?
BAKX THERAPEUTICS has raised $25M in total.
What has the press written about BAKX THERAPEUTICS?
Parsers VC has collected 2 articles mentioning BAKX THERAPEUTICS, among them “Ipsen : BAKX collaboration-27 July 2021” (Jul 27, 2021).
Is BAKX THERAPEUTICS still active?
Yes, BAKX THERAPEUTICS is active; its latest activity on Parsers VC dates from Nov 18, 2021.